Overview of Current Biomarkers in Kidney Disease

Joseph V. Bonventre MD PhD
Chief, Renal Division
Chief, Biomedical Engineering Division
Brigham and Women’s Hospital
Harvard Medical School

Disclosure: JVB is co-inventor on KIM-1 patents that have been licensed to a number of companies including Johnson and Johnson, Genzyme, R and D, BioAssay Works, and BiogenIdec

Outline

• AKI Biomarkers
• Lessons Learned from Success in Identification and Qualification of Kidney Biomarkers to Guide Drug Development
• The Gold Standard Problem
• Clinical studies of Biomarkers in AKI
• Challenges with CKD Biomarkers
• Biomarkers provide insight into pathophysiology

Characteristics of an Ideal Biomarker for AKI

• Easy to measure in easily obtainable fluids: urine or blood
• Sensitive enough to pick up meaningful injury prior to functional changes
• Produced by a specific segment of the kidney tubule or kidney endothelium
• Distinguishes tubular from prerenal and glomerular injury
• Stable in the blood or urine, devoid of interferences with other substances, and unaffected by chemical composition of the urine, including ionic strength and pH among others
• Increases in levels are predictive of severity of acute injury and chronic sequelae
• Decreases in levels are reflective of recovery
• Understandable function of the marker in the kidney
FDA’s Critical Path Initiative

“Additional biomarkers (quantitative measures of biological effects that provide informative links between mechanism of action and clinical effectiveness) and additional surrogate markers (quantitative measures that can predict effectiveness) are needed to guide product development.”
In the first use of a framework allowing submission of a single application to the 2 agencies, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) will allow drug companies to submit the results of 7 new tests that evaluate kidney toxicity... (FDA news release, 6/17/2008).

The tests measure levels of 7 key biomarker proteins found in urine that can provide information about drug-induced damage to kidney cells (renal toxicity). The new biomarkers are:

- KIM-1
- Albumin
- Clusterin
- Trefoil factor-3
- Cystatin C
- Total protein
- Beta-2 microglobulin

Tubular Injury Biomarkers

Glomerular changes or impaired tubular reabsorption biomarkers

Flow chart explaining the proposed limited clinical translational use of the new renal biomarkers

Outline

• AKI Biomarkers
• Lessons Learned from Success in Identification and Qualification of Kidney Biomarkers to Guide Drug Development
• The Gold Standard Problem
• Clinical studies of Biomarkers in AKI
• Challenges with CKD Biomarkers
• Biomarkers provide insight into pathophysiology

Diagnostic performance of the first postoperative value of urine IL-18, urine NGAL, and plasma NGAL for the detection of AKI.

- Urine IL-18 (pg/mL) 0.74
- Urine NGAL (ng/mL) 0.67
- Plasma NGAL (ng/mL) 0.70

Parikh C R et al. JASN 2011;22:1748-1757

©2011 by American Society of Nephrology
Tubular Damage

KIM-1, L-FABP, α-GST (albumin and NGAL)

GFR
Creat, Cystatin C, KDIGO Stage

Inflammation
NGAL, IL-18

KDIGO Stage

Injury Marker
Inflammation Marker
GFR Marker
Kidney Injury

+ + +
+ + +
+ + +
+ + +
- + -
- + -
- + -
- + -

Tubular Damage

+/− Inflammation

GFR
Creatinine, KDIGO Stage

Difficulty with Creatinine

Injury
Inflammation

GFR
Creatinine, KDIGO Stage

Potential Context of Interpretation of AKI Markers

Prevalence = 20% (20/100)

Imperfect gold standard picks up 16 of 20 true positives

Imperfect gold standard picks up 64 of 80 true negatives

Perfect Biomarker Performance in Setting of Imperfect Gold Standard

Perfect Biomarker

Sensitivity = 50%

Specificity = 94%

(16 of 32)

(64 of 68)

Effect of Prevalence of AKI on Apparent Specificity and Sensitivity of a Perfect Biomarker when AKI Definition is Assumed 95% Sensitive and 90% Specific

Prevalence

Apparent Specificity

Apparent Sensitivity
Plasma NGAL as a Predictor of AKI and Clinical Outcomes

<table>
<thead>
<tr>
<th>ROC analysis</th>
<th>At cutoff [HR &gt; 1]</th>
<th>AUC ROC (95% CI)</th>
<th>Sensitivity (95% CI)</th>
<th>Specificity (95% CI)</th>
<th>PPV (95% CI)</th>
<th>NPV (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKI within 6 h</td>
<td>0.78 (0.65-0.90)</td>
<td>0.73 (0.65-0.82)</td>
<td>0.81 (0.75-0.88)</td>
<td>0.24 (0.13-0.34)</td>
<td>0.87 (0.79-0.95)</td>
<td></td>
</tr>
<tr>
<td>AKI within 5 days</td>
<td>0.67 (0.59-0.75)</td>
<td>0.66 (0.57-0.75)</td>
<td>0.80 (0.74-0.86)</td>
<td>0.66 (0.54-0.77)</td>
<td>0.87 (0.79-0.95)</td>
<td></td>
</tr>
<tr>
<td>RRT within ICU stay</td>
<td>0.82 (0.70-0.95)</td>
<td>0.87 (0.80-0.94)</td>
<td>0.65 (0.60-0.71)</td>
<td>0.12 (0.06-0.19)</td>
<td>0.99 (0.90-1.00)</td>
<td></td>
</tr>
<tr>
<td>ICU mortality</td>
<td>0.67 (0.58-0.77)</td>
<td>0.60 (0.52-0.73)</td>
<td>0.61 (0.54-0.70)</td>
<td>0.73 (0.63-0.82)</td>
<td>0.88 (0.78-0.95)</td>
<td></td>
</tr>
<tr>
<td>RRT + ICU mortality</td>
<td>0.68 (0.59-0.77)</td>
<td>0.60 (0.52-0.73)</td>
<td>0.61 (0.54-0.70)</td>
<td>0.73 (0.63-0.82)</td>
<td>0.88 (0.78-0.95)</td>
<td></td>
</tr>
</tbody>
</table>

301 ICU patients; 133 (44%) developed AKI during ICU stay

Cruz...Ronco Intensive Care Med.36:444-451, 2010

ROC curve for peak post-operative SCr after cisplatin therapy for mesothelioma (using 24h KIM-1 ≥ 2 ng/mg Ucr as gold standard)

AUC-ROC = 0.55

Admission-to-discharge percentage change in GFR grouped by presence or absence of hemoconcentration.


Copyright © American Heart Association
Survival curves grouped by presence or absence of hemoconcentration after adjustment for baseline characteristics.

Kidney Safety Project
Site Initiation – Cisplatin Study

University of Texas
MD Anderson Cancer Center
October 17, 2012

Brigham & Women’s Hospital
Dana-Farber Cancer Institute
November 2012

Study Team – BWH Harvard Partners DFCI

- Sus Waikar, MD
  Principal Investigator
  Brigham & Women’s Hospital
  (617) 732-8473 phone
  swaikar@partners.org

- Vicky Vergara
  Research Coordinator
  Dana-Farber Cancer Institute
  (617) 632-5260 phone
  victoria_vergara@dfci.harvard.edu

- Robert Haddad, MD
  Center for Head & Neck Oncology
  Dana-Farber Cancer Institute
  (617) 632-3090 phone
  robert_haddad@dfci.harvard.edu
Cisplatin Study

A Prospective Observational Study of Urinary Biomarkers of Nephrotoxicity in Cancer Patients Receiving Cisplatin Chemotherapy

They will assess the performance of a large panel of kidney biomarkers in patients with various cancers who are scheduled to receive high-dose cisplatin chemotherapy and compare these with cancer control patients. Results from this study will be used to support the clinical qualification of biomarkers for drug-induced kidney injury.

Scheduled Visits & Sample Collection Time-Points

Urinary and Blood samples (serum BUN, creatinine, cystatin C, sodium, and spot urine samples for novel biomarkers)

The Creatinine Normalization Issue

Waikar et al. Kidney Int. 2010
Outline

- AKI Biomarkers
- Lessons Learned from Success in Identification and Qualification of Kidney Biomarkers to Guide Drug Development
- The Gold Standard Problem
- Clinical studies of Biomarkers in AKI
- Challenges with CKD Biomarkers
- Biomarkers provide insight into pathophysiology

Criteria for an Ideal Biomarker for CKD

- Easy to measure in easily obtainable fluids: urine or blood
- Produced by a specific segment of the kidney tubule or kidney endothelium
- Stable in the blood or urine, devoid of interferences with other substances, and unaffected by chemical composition of the urine, including ionic strength and pH among others
- Levels are predictive of clinically significant outcome
- Prognostic: Levels predict rapid progressors from others so that aggressive therapies can be personalized and clinical trials of new therapeutics can be facilitated.
- Progression: Levels reflect change in disease state over time. Usually require repeated measurements.
- Understandable function of the marker in the kidney

Conceptual Framework for the CKD Biomarker (CKDBiocon) Consortium
AKI Leads to CKD

AKI  CKD

CKD Predisposes to AKI

Many Factors contribute to the Progression of Kidney Disease

Tubular Injury, Oxidative Stress, Endothelial Injury, Fibrosis, Metabolic Dysfunction, Systemic Inflammation, Glomerular Injury

The more biomarkers we have for these pathways the more likely we are to be able to predict rates of progression and intervene effectively to alter the outcome.

Outline

- AKI Biomarkers
- Lessons Learned from Success in Identification and Qualification of Kidney Biomarkers to Guide Drug Development
- The Gold Standard Problem
- Clinical studies of Biomarkers in AKI
- Challenges with CKD Biomarkers
- Biomarkers provide insight into pathophysiology
Biomarkers Reveal Important Aspects of Underlying Pathophysiological Disease Processes

Area under Receiver Operator Curve for Several Biomarkers for Development of KDIGO stage 2 or 3 within 12 hours of Sample Collection

Kashani et al. Critical Care 17:R25, 2013

Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury
Kashani et al. Critical Care 17:R25, 2013
In Vivo Cell Cycle Analysis

Preparation for mitosis 19%
DNA synthesis 39%
Synthesis required for DNA synthesis 40%
Mitosis 3%
Quiescence (variable)

BrdU uptake

100% G2/M
S
G1

Ki67

Yang et al. Nature Medicine 2010

In Vivo Cell Cycle Analysis in AKI

Moderate IRI
G2/M
S
G1

Unilateral IRI
AAN

Plasma KIM-1 is elevated in I/R mice

Plasma Creatinine

Plasma KIM-1

Absolute Urinary KIM-1

Normalized Urinary KIM-1

* P<0.001
Elevation of Plasma KIM-1 in patients who developed AKI after CPB

Normalized urinary KIM-1

Plasma KIM-1

* p<0.05, significant difference from baseline

* p<0.05, significant difference between AKI and non-AKI group (N=9)

How can Novel Biomarkers, assuming they bring new information about Kidney Disease, be a “False Dawn?”

• Their insight into pathophysiology is unappreciated and unincorporated into our approaches to therapies. How can we ignore new, easy to obtain information about pathophysiology, when we have no therapies???
• We do not spend enough effort understanding the origins, specificity and insight into kidney pathobiology they reveal.
• We rely on inadequate “gold standards” to validate the biomarker.
• In the case of CKD we are likely asking too much of a single biomarker given the complexity of disease process and the multiple factors that affect progression over time.

Biomarkers Provide Much More Insight Than This
Outline

- AKI Biomarkers
- Lessons Learned from Success in Identification and Qualification of Kidney Biomarkers to Guide Drug Development
- The Gold Standard Problem
- Clinical studies of Biomarkers in AKI
- Challenges with CKD Biomarkers
- Biomarkers provide insight into pathophysiology

Collaborators

- Won Han
- Hari Ichimura
- Eileen O’Leary
- Venkata Sabbisetti
- Vishal Vaidya
- Sus Waikar
- Mike Ferguson
- Michele Sanicola
- Richard Cate
- Veronique Bailly
- Ravi Thadhani
- Rebecca Betansky
- Victoria Ramirez
- Gerardo Gamba
- Norma Bobadilla
- R. J. Ploeg
- W. N. Nijboer
- Harry Van Goor
- Mirjan Van Timmeran
- John Himmelfarb
- Ron Brown
- Frank Dieterle
- Peter Feig
- Peter Goering
- Bertrand Jaber
- Orléas Liangos
- Andrea Krammer
- Walter Prozialeck
- Bernd Schroeppele
- Frank Sistare
- Theo Shurrs
- Jim Tumlin
- John Vella
- PSTC
- R. J. Ploeg
- W. N. Nijboer
- Harry Van Goor
- Mirjan Van Timmeran
- John Himmelfarb
- Ron Brown
- Frank Dieterle
- Peter Feig
- Peter Goering
- Bertrand Jaber
- Orléas Liangos
- Andrea Krammer
- Walter Prozialeck
- Bernd Schroeppele
- Frank Sistare
- Theo Shurrs
- Jim Tumlin
- John Vella
- PSTC